

Alexander Schuhmacher

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1381773/alexander-schuhmacher-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

352
citations

7
h-index

18
g-index

38
ext. papers

470
ext. citations

8
avg, IF

3.95
L-index

#	Paper	IF	Citations
32	Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence. <i>Drug Discovery Today</i> , 2021 , 26, 2226-2231	8.8	2
31	Translational precision medicine: an industry perspective. <i>Journal of Translational Medicine</i> , 2021 , 19, 245	8.5	12
30	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. <i>Drug Discovery Today</i> , 2021 , 26, 2786-2793	8.8	1
29	R&D efficiency of leading pharmaceutical companies - A 20-year analysis. <i>Drug Discovery Today</i> , 2021 , 26, 1784-1789	8.8	4
28	The upside of being a digital pharma player. <i>Drug Discovery Today</i> , 2020 , 25, 1569-1574	8.8	23
27	Innovation: Key to Success in the Pharmaceutical Industry 2018 , 1-16		0
26	Leading Pharmaceutical Innovation 2018 ,		14
25	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. <i>Journal of Translational Medicine</i> , 2018 , 16, 119	8.5	22
24	Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D testing model. <i>International Journal of Bioprinting</i> , 2018 , 4, 123	6.2	12
23	Introduction to the Book 2016 , 1-9		
22	Translational Development 2016 , 224-243		
21	Forty Years of Innovation in Biopharmaceuticals [Will the Next 40 Years Be as Revolutionary? 2016 , 244-275		
20	Vaccines: Where Inertia, Innovation, and Revolution Create Value, Simultaneously and Quietly 2016 , 276-307		
19	The Patient-Centric Pharma Company: Evolution, Reboot, or Revolution? 2016 , 308-333		
18	The Pharmaceutical Industry is Opening Its R&D Boundaries 2016 , 334-361		1
17	Out-Licensing in Pharmaceutical Research and Development 2016 , 362-381		
16	Trends and Innovations in Pharmaceutical R&D Outsourcing 2016 , 382-399		

15	New Innovation Models in Pharmaceutical R&D 2016 , 400-415		1
14	The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation 2016 , 416-447		1
13	Global Epidemiological Developments 2016 , 10-43		1
12	The Role of Modern Portfolio Management in Pharma Innovation 2016 , 448-459		1
11	Patent Management Throughout the Innovation Life Cycle 2016 , 460-474		
10	The Value of Pharmaceutical Innovation: Concepts and Assessment 2016 , 44-59		
9	A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities 2016 , 60-79		5
8	Financing Pharmaceutical Innovation 2016 , 80-105		
7	Challenges and Options for Drug Discovery 2016 , 106-139		1
6	Translational Medicine: Enabling the Proof of Concepts 2016 , 140-159		
5	Preclinical Safety and Risk Assessment 2016 , 160-181		
4	Developing Commercial Solutions for Therapeutic Proteins 2016 , 182-201		
3	Changing R&D models in research-based pharmaceutical companies. <i>Journal of Translational Medicine</i> , 2016 , 14, 105	8.5	166
2	Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. <i>Perspectives on Sustainable Growth</i> , 2015 , 39-68		
1	Models for open innovation in the pharmaceutical industry. <i>Drug Discovery Today</i> , 2013 , 18, 1133-7	8.8	76